SCHEMBL3779100

SCHEMBL3779100

O=C(Nc1ccccc1)c1cn2cc(-c3cnccn3)ccc2n1

nearest known ligand 0.78

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.78
CYP2C9 P11712 1/20 0.78
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.52
CYP3A4 P08684 1/20 0.48
EGLN1 Q9GZT9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770088 0.87 NR4A2 (1.00) NR4A2CYP2C9NPC1RAB9AEGLN1
SCHEMBL15419017 0.84 NR4A2 (0.78) NR4A2CYP2C9NPC1RAB9ACYP3A4
SCHEMBL3767823 0.84 CYP2C9 (0.67) NR4A2CYP2C9NPC1RAB9ACYP3A4
SCHEMBL3772210 0.82 NR4A2 (0.71) NR4A2CYP2C9NPC1RAB9ASMN1; SMN2
SCHEMBL3778496 0.82 NR4A2 (0.78) NR4A2CYP2C9NPC1RAB9AEGLN1
SCHEMBL3366348 0.82 CYP2C9 (0.73) NR4A2CYP2C9NPC1RAB9AEGLN1
SCHEMBL3776387 0.81 CYP2C9 (0.66) NR4A2CYP2C9NPC1RAB9AEGLN1
SCHEMBL3766988 0.81 NR4A2 (0.72) NR4A2CYP2C9NPC1RAB9AEGLN1
Hydrochloric Acid SCHEMBL3771634 0.80 NR4A2 (0.70) NR4A2CYP2C9NPC1RAB9AEGLN1
SCHEMBL3778993 0.80 NR4A2 (0.71) NR4A2CYP2C9NPC1RAB9AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225240-B1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2014-01-22 EP claimed
US-8314109-B2 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2012-11-20 US claimed
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US claimed
US-8691990-B2 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2014-04-08 US disclosed
EP-2225240-B1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2014-01-22 EP disclosed
US-20130041152-A1 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF PEYRONEL JEAN-FRANCOIS (FR) 2013-02-14 US disclosed
US-8314109-B2 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2012-11-20 US disclosed
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041152-A1 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF XDH, REN, IDH2 NR4A2 2105/4885CYP2C9 209/4885NPC1 2354/4885
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF REN, IDH2, GLS NR4A2 1987/4885CYP2C9 231/4885NPC1 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.